Research programme: cancer and autoimmune disorder therapeutics - Gliknik

Drug Profile

Research programme: cancer and autoimmune disorder therapeutics - Gliknik

Alternative Names: CD20 Stradobody; GB-4542; Rituximab biobetter - Gliknik; Stradobodies™; Stradomers™

Latest Information Update: 03 Mar 2016

Price : $50

At a glance

  • Originator Gliknik
  • Class
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 03 Mar 2016 Preclinical development is ongoing for Cancer and Autoimmune disorders in USA
  • 03 Oct 2011 Preclinical trials in Cancer in USA (unspecified route)
  • 03 Oct 2011 Gliknik receives SBIR grant from the National Cancer Institute for the development of monoclonal antibody-like compounds in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top